A series of experiments is proposed to investigate the comparative behavioral pharmacology and abuse liability of novel sedative drugs, including prescription sedative-hypnotics and the currently abused """"""""club drugs"""""""" GHB and ketamine which are considered to represent a significant public health problem. Drugs will be administered under double-blind conditions in capsules, oral solutions, or intramuscular injections. The effects of drug administration will be assessed using various subjective, psychomotor performance, cognitive, memory and physiological measures. Experiments 1-6 will provide detailed dose-effect, time-course, and relative potency data. A series of three dose-effect experiments will assess subjective effects, performance impairment, and abused liability of a range of doses (including high doses) of several novel abused sedative drugs in volunteers with histories of drug abuse who will reside on a residential research laboratory: GHB vs. triazolam (Exp. 1); ketamine vs. midazolam (Exp. 2); and clonidine vs. alprazolam (Exp. 3). Three-dose-effect experiments in normal subjects will focus on evaluation of subtle cognitive and memory effects at relatively low doses: GHB vs. triazolam (Exp. 4); ketamine vs. midazolam (Exp. 5); and zaleplon vs. triazolam (Exp. 6). Exp 7 will examine the interaction of GHB with ethanol and compare this to the interaction of triazolam with ethanol. The final two experiments will extend work on comparative pharmacology by using drug discrimination procedures to differentiate between GHB and triazolam (Exp 8) and between zolpidem and triazolam (Exp. 9). Because the novel drugs proposed for study have unique cellular sites of action, this research may provide new insights about basic behavioral and pharmacological mechanisms of action. These studies will also have implications for recreational abuse of sedatives as well as the toxic consequence of such use. This comparative pharmacology research program, with its particular focus on sedatives, may ultimately contribute to an understanding of a biological basis of sedation and sleep, and should contribute to efforts to develop and identify new classes of sedative hypnotic compounds which have reduced potential for performance and cognitive impairment and abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003889-20
Application #
6605890
Study Section
Special Emphasis Panel (ZRG1-BBBP-1 (01))
Program Officer
Schnur, Paul
Project Start
1984-07-01
Project End
2007-05-31
Budget Start
2003-06-11
Budget End
2004-05-31
Support Year
20
Fiscal Year
2003
Total Cost
$433,756
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Barrett, Frederick S; Carbonaro, Theresa M; Hurwitz, Ethan et al. (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. Psychopharmacology (Berl) 235:2915-2927
Foncelle, Alexandre; Mendes, Alexandre; J?drzejewska-Szmek, Joanna et al. (2018) Modulation of Spike-Timing Dependent Plasticity: Towards the Inclusion of a Third Factor in Computational Models. Front Comput Neurosci 12:49
Carbonaro, Theresa M; Johnson, Matthew W; Hurwitz, Ethan et al. (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology (Berl) 235:521-534
Griffiths, Roland R; Johnson, Matthew W; Richards, William A et al. (2018) Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol 32:49-69
J?drzejewski-Szmek, Zbigniew; Abrahao, Karina P; J?drzejewska-Szmek, Joanna et al. (2018) Parameter Optimization Using Covariance Matrix Adaptation-Evolutionary Strategy (CMA-ES), an Approach to Investigate Differences in Channel Properties Between Neuron Subtypes. Front Neuroinform 12:47
Barrett, Frederick S; Griffiths, Roland R (2018) Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Curr Top Behav Neurosci 36:393-430
Johnson, Matthew W; Garcia-Romeu, Albert; Griffiths, Roland R (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 43:55-60
Barrett, Frederick S; Robbins, Hollis; Smooke, David et al. (2017) Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. Front Psychol 8:1238
Johnson, Matthew W; Griffiths, Roland R (2017) Potential Therapeutic Effects of Psilocybin. Neurotherapeutics 14:734-740
Johnson, Matthew W; Garcia-Romeu, Albert; Johnson, Patrick S et al. (2017) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol 31:841-850

Showing the most recent 10 out of 110 publications